


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:


1. (Previously Presented) A compound of Formula (I)



(I)

in which:

R represents -H, -YCR5R6COX, monocyclic, bicyclic or tricyclic aryl or heteroaryl optionally substituted by groups -YCR5R6COX, halogens, nitro, hydroxy, alkyl, and alkoxy, possibly substituted by halogens, monocyclic, bicyclic or tricyclic arylalkyl or heteroarylalkyl in which the aryl or heteroaryl are optionally substituted by the groups -YCR5R6COX, halogens, nitro, hydroxy, alkyl, and alkoxy, possibly substituted by halogens, or a charged heteroaryl :



in which the positive charge is balanced by a suitable negative counterion;

m represents 0-1


n represents 0-3 provided that when n represents 1, R3 and R4, which may be the same or different, are selected from H or alkyl C₁-C₅;

when n represents 2 or 3, R3 is equal to R4 and represents H;

p represents 0-1

X represents -OH, -O-alkyl C₁-C₃;

R1 and R2, which may be the same or different, are selected from: -H; alkyl C₁-C₅;
-alkoxy, optionally substituted by halogens; -phenoxy, possibly substituted by halogens, nitro,
hydroxy, alkyls; -benzyloxy, possibly substituted by halogens, nitro, hydroxy, alkyls;
-COX; or together with COX of general formula (I) form a cycle of the type:



R5 and R6, which may be the same or different, are selected from the groups listed for R1 and R2;

Q and Z, which may be the same or different, are selected from: NH, O, S, -NHC(O)O-, NHC(O)NH-, -NHC(O)S-, -OC(O)NH-, -NHC(S)O-, -NHC(S)NH-, -C(O)NH-;

and Y represents O or S.

2. (Canceled).
3. (Previously Presented) A pharmaceutical composition containing as its active ingredient a formula (I) compound according to claim 1 and at least one pharmaceutically acceptable excipient and/or diluent.

4. (Previously Presented) The composition according to claim 3, in the form of tablets, capsules, pills, sachets, vials, powders, suppositories, solutions, suspensions, emulsions or liposomal preparations.

5. (Previously Presented) The composition according to claim 4, which can be administered by the enteral or parenteral routes.

6.-7. (Canceled).

8. (Previously Presented) A method of treating heart failure comprising administering to a subject an effective amount of a compound of claim 1.

9. (Previously Presented) A method of treating hyperlipaemia comprising administering to a subject an effective amount of a compound of claim 1.

10. (Previously Presented) A method of treating atherosclerosis comprising administering to a subject an effective amount of a compound of claim 1.

11. (New) The compound methyl 2-[3-[5-(4-nitrophenyl)furfuryl-oxy]phenylthio]isobutyrate.